Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 6,018 shares of the business’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the transaction, the chief financial officer owned 51,000 shares in the company, valued at $2,233,800. This represents a 10.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Enliven Therapeutics Price Performance

ELVN traded up $0.86 on Monday, hitting $45.96. The company had a trading volume of 2,517,152 shares, compared to its average volume of 1,260,113. Enliven Therapeutics, Inc. has a 52-week low of $14.78 and a 52-week high of $48.53. The stock has a fifty day simple moving average of $41.81 and a 200-day simple moving average of $31.59. The firm has a market capitalization of $2.80 billion, a P/E ratio of -27.52 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. Equities research analysts expect that Enliven Therapeutics, Inc. will post -1.71 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages recently weighed in on ELVN. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. HC Wainwright boosted their target price on shares of Enliven Therapeutics from $48.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, March 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Stifel Nicolaus began coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 9th. They issued a “buy” rating and a $60.00 price target for the company. Finally, Guggenheim initiated coverage on shares of Enliven Therapeutics in a research report on Tuesday, May 12th. They set a “buy” rating and a $80.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $63.40.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vestal Point Capital LP increased its holdings in shares of Enliven Therapeutics by 230.2% during the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock valued at $58,982,000 after acquiring an additional 2,670,000 shares in the last quarter. Siren L.L.C. purchased a new stake in Enliven Therapeutics during the 1st quarter valued at about $29,252,000. Affinity Asset Advisors LLC bought a new stake in Enliven Therapeutics during the 1st quarter valued at about $23,007,000. TCG Crossover Management LLC bought a new stake in Enliven Therapeutics during the 2nd quarter valued at about $9,990,000. Finally, Duquesne Family Office LLC raised its holdings in Enliven Therapeutics by 104.6% in the third quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after buying an additional 484,405 shares during the last quarter. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.